Current Research

Mallinckrodt IIT(Acthar Gel)

Synopsis

This is a phase IV clinical trial of a repository corticotropin injection (H.P. Acthar Gel) in order to treat non-infectious retinal vasculitis. Throughout the duration of this open label study, the safety and efficacy of the treatment will be evaluated. Participation is limited to patients 18 years of age or older with retinal vasculitis associated with a non-infectious ocular inflammatory disease. Patients will be followed for 24 weeks over the course of 6 office visits.

Mallinckrodt Multicenter MNK61074105(Acthar Gel)

Synopsis

This is a phase IV clinical trial of a repository corticotropin injection (H.P. Acthar Gel) in order to treat non-infectious intermediate uveitis, posterior uveitis, or panuveitis (NIPPU). Throughout the duration of this open label study, the safety and efficacy of the treatment will be evaluated. Participation is limited to patients 18 years of age or older with active NIPPU. Patients will be followed for 44 weeks over the course of 13 visits.

 

  • Make a donation Visit our store Make an appointment Join our mailing list Newsletters Walk for Vision Saving Vision One Step at a Time LEARN MORE

  • Educational Audio

    Click here to listen to
     Uveitis and Steroid-Sparing Therapy

    Presented by C. Stephen Foster, MD, FACS, FACR

    Audio-Digest Ophthalmology Volume 56, Issue 15

  • Mia Resendes

  • Twitter Feed

    • Blog

    Skip to toolbar